European Task Force on Atopic Dermatitis (ETFAD): position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics

Jacob P Thyssen, Christian Vestergaard, Sebastien Barbarot, Marjolein S de Bruin-Weller, Thomas Bieber, Alain Taieb, Julien Seneschal, Michael J Cork, Carle Paul, Carsten Flohr, Stephan Weidinger, Magdalena Trzeciak, Thomas Werfel, Annice Heratizadeh, Ulf Darsow, Dagmar Simon, Antonio Torrelo, Pavel V Chernyshov, Jean-Francois Stalder, Carlo GelmettiZsuzsanna Szalai, Åke Svensson, Laura B von Kobyletzki, Linda De Raeve, Regina Fölster-Holst, Stéphanie Christen-Zaech, Dirk Jan Hijnen, Uwe Gieler, Jan Gutermuth, Christine Bangert, Phyllis I Spuls, Barbara Kunz, Johannes Ring, Andreas Wollenberg, Mette Deleuran

Onderzoeksoutput: Letter

6 Citaten (Scopus)

Samenvatting

The coronavirus disease 2019 (COVID-19) pandemic is caused by rapid spread of different strains of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The severity of infection ranges from mild, or even asymptomatic, to very severe. Signs and symptoms include fatigue, fever, exanthemas, upper respiratory illness, loss of smell and taste, pneumonia, severe acute respiratory syndrome, and multi-organ failure. Risk factors for a severe or lethal course include age, male gender, obesity, diabetes, cardiovascular disease, and immune suppression1 .

Originele taal-2English
Pagina's (van-tot)e308-e311
Aantal pagina's2
TijdschriftJournal of the European Academy of Dermatology and Venereology
Volume35
Nummer van het tijdschrift5
DOI's
StatusPublished - mei 2021

Bibliografische nota

This article is protected by copyright. All rights reserved.

Vingerafdruk

Duik in de onderzoeksthema's van 'European Task Force on Atopic Dermatitis (ETFAD): position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics'. Samen vormen ze een unieke vingerafdruk.

Citeer dit